Description
Flupirtine maleate is an agonist at voltage-gated KCNQ/Kv7 K+ channels; opening of these channels on neurons facilitates M-current generation and decreases axonal excitability. In addition to its modulation of K+ channels, flupirtine maleate also inhibits NMDA receptors and shifts gating of GABA-A receptors to decrease circulating GABA concentrations. Flupirtine maleate is an effective non-sedative analgesic, showing benefit in clinical trials of neurosurgical patients. In animal models, this compound also attenuates development of and reverses established pulmonary arterial hypertension, suggesting antihypertensive activity.
References
Yadav G, Choupoo S, Das SK, et al. Evaluating the Role of Flupirtine for Postcraniotomy Pain and Compare it With Diclofenac Sodium: A Prospective, Randomized, Double Blind, Placebo-controlled Study. J Neurosurg Anesthesiol. 2013 Jun 11. [Epub ahead of print]. PMID: 23764718.
Fleckenstein J, Sittl R, Averbeck B, et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial. J Transl Med. 2013 Feb 8;11:34. PMID: 23394517.
Klinger F, Geier P, Dorostkar MM, et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine. Br J Pharmacol. 2012 Jul;166(5):1631-42. PMID: 22188423.
Harish S, Bhuvana K, Bengalorkar GM, et al. Flupirtine: Clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2012 Apr;28(2):172-7. PMID: 22557738.
Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs. 2010 Oct;24(10):867-81. PMID: 20839897.
Morecroft I, Murray A, Nilsen M, et al. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 Aug;157(7):1241-9. PMID: 19508393.
